acetazolamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	56	59-66-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: acetazolamide acetamox acetazolamid cidamex nephramide acetazolamide sodium	One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) Molecular weight: 222.24 Formula: C4H6N4O3S2 CLOGP: -0.98 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 115.04 ALOGS: -1.90 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

acetazolamide
acetamox
acetazolamid
cidamex
nephramide
acetazolamide sodium

One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)

Molecular weight: 222.24
Formula: C4H6N4O3S2
CLOGP: -0.98
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 115.04
ALOGS: -1.90
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.75	g	O
0.75	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.64 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	90 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	75.14 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.37 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.65 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.04 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	13 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 27, 1953	FDA	TEVA BRANDED PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angle closure glaucoma	153.93	17.40	39	6925	1995	50596165
Idiopathic intracranial hypertension	148.35	17.40	39	6925	2310	50595850
Hair follicle tumour benign	128.89	17.40	25	6939	362	50597798
Metabolic acidosis	118.33	17.40	71	6893	38754	50559406
Papilloedema	111.56	17.40	34	6930	3439	50594721
Intraocular pressure increased	99.93	17.40	35	6929	5481	50592679
Choroidal effusion	95.47	17.40	20	6944	434	50597726
Intracranial pressure increased	84.84	17.40	29	6935	4223	50593937
Off label use	76.15	17.40	187	6777	474239	50123921
Choroidal detachment	67.42	17.40	13	6951	182	50597978
Complications of bone marrow transplant	56.13	17.40	13	6951	453	50597707
Hepatosplenic T-cell lymphoma	53.12	17.40	13	6951	575	50597585
Macular detachment	44.24	17.40	8	6956	77	50598083
Retinal detachment	41.03	17.40	18	6946	5111	50593049
Flat anterior chamber of eye	40.21	17.40	7	6957	53	50598107
Intellectual disability	39.85	17.40	11	6953	783	50597377
Hypercapnia	39.49	17.40	17	6947	4610	50593550
Aggression	38.38	17.40	28	6936	21088	50577072
Corneal oedema	37.89	17.40	12	6952	1375	50596785
Acute generalised exanthematous pustulosis	37.03	17.40	20	6944	8918	50589242
Visual impairment	36.56	17.40	46	6918	68229	50529931
Glaucoma	36.00	17.40	24	6940	15662	50582498
Photophobia	34.70	17.40	23	6941	14864	50583296
Hypotony of eye	34.00	17.40	7	6957	139	50598021
Ophthalmic vein thrombosis	33.58	17.40	7	6957	148	50598012
Lens dislocation	31.62	17.40	5	6959	19	50598141
Visual field defect	29.87	17.40	15	6949	5764	50592396
Myopia	28.93	17.40	10	6954	1503	50596657
Cerebral venous sinus thrombosis	27.98	17.40	10	6954	1658	50596502
Persecutory delusion	27.96	17.40	11	6953	2376	50595784
Psychiatric decompensation	26.74	17.40	9	6955	1249	50596911
Retinopathy haemorrhagic	26.56	17.40	4	6960	10	50598150
Dysphoria	26.47	17.40	13	6951	4761	50593399
Myasthenic syndrome	26.28	17.40	6	6958	196	50597964
Product contamination microbial	26.05	17.40	6	6958	204	50597956
Iridocyclitis	25.97	17.40	10	6954	2039	50596121
Haemorrhagic diathesis	25.69	17.40	12	6952	3936	50594224
Vision blurred	24.50	17.40	41	6923	78606	50519554
Retroperitoneal oedema	24.24	17.40	4	6960	21	50598139
Toxic leukoencephalopathy	23.69	17.40	7	6957	636	50597524
Appetite disorder	23.44	17.40	13	6951	6101	50592059
Ocular pemphigoid	23.13	17.40	4	6960	29	50598131
CSF pressure increased	23.07	17.40	5	6959	128	50598032
Cross sensitivity reaction	22.80	17.40	9	6955	1960	50596200
Transmission of an infectious agent via product	22.68	17.40	5	6959	139	50598021
Ocular surface disease	22.57	17.40	4	6960	34	50598126
Optic disc haemorrhage	22.07	17.40	4	6960	39	50598121
Product use in unapproved indication	22.05	17.40	49	6915	115770	50482390
Drug ineffective	21.81	17.40	189	6775	819144	49779016
Arthritis infective	21.79	17.40	12	6952	5557	50592603
Acute respiratory failure	21.45	17.40	23	6941	28759	50569401
Sickle cell anaemia with crisis	21.18	17.40	11	6953	4532	50593628
Diplopia	21.09	17.40	19	6945	19241	50578919
Lactic acidosis	20.32	17.40	24	6940	33331	50564829
Acidosis	19.58	17.40	14	6950	10213	50587947
Meningitis aseptic	19.20	17.40	10	6954	4142	50594018
Conjunctival hyperaemia	18.93	17.40	8	6956	2074	50596086
Foetal exposure during pregnancy	18.88	17.40	21	6943	27338	50570822
Vitreous disorder	18.78	17.40	4	6960	94	50598066
Dropped head syndrome	18.36	17.40	4	6960	105	50598055
Splenomegaly	17.98	17.40	13	6951	9647	50588513
Skin warm	17.97	17.40	10	6954	4725	50593435
Retinal vascular occlusion	17.88	17.40	5	6959	373	50597787
Nasal flaring	17.70	17.40	3	6961	19	50598141

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intraocular pressure increased	159.59	21.07	46	3269	4743	29566469
Choroidal detachment	128.98	21.07	24	3291	343	29570869
Metabolic acidosis	109.32	21.07	62	3253	37600	29533612
Angle closure glaucoma	98.55	21.07	22	3293	803	29570409
Choroidal effusion	86.66	21.07	15	3300	138	29571074
Toxic epidermal necrolysis	63.93	21.07	34	3281	18119	29553093
Congenital emphysema	48.58	21.07	6	3309	0	29571212
Ocular surface disease	42.65	21.07	7	3308	45	29571167
Visual acuity reduced	41.75	21.07	24	3291	14852	29556360
Hyphaema	37.00	21.07	9	3306	479	29570733
Glaucoma	35.79	21.07	16	3299	5841	29565371
Drug ineffective	31.12	21.07	100	3215	363070	29208142
Hypochloraemia	31.10	21.07	8	3307	535	29570677
Burkholderia test positive	30.60	21.07	9	3306	990	29570222
Corneal oedema	29.42	21.07	9	3306	1133	29570079
Acidosis hyperchloraemic	28.93	21.07	7	3308	364	29570848
Photocoagulation	27.99	21.07	4	3311	8	29571204
Drug reaction with eosinophilia and systemic symptoms	26.01	21.07	23	3292	27969	29543243
Trabeculectomy	25.57	21.07	4	3311	18	29571194
Product contamination microbial	25.47	21.07	7	3308	604	29570608
Off label use	24.05	21.07	81	3234	300719	29270493
Dysmetria	23.40	21.07	6	3309	396	29570816
Crystalluria	23.21	21.07	6	3309	409	29570803
Hypocapnia	22.90	21.07	5	3310	164	29571048
Transmission of an infectious agent via product	22.62	21.07	5	3310	174	29571038
Hypercapnia	22.19	21.07	10	3305	3716	29567496
Visual acuity tests abnormal	21.98	21.07	4	3311	50	29571162
Corneal opacity	21.95	21.07	6	3309	507	29570705
Endophthalmitis	21.38	21.07	9	3306	2839	29568373
Intraocular pressure decreased	21.12	21.07	4	3311	63	29571149

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angle closure glaucoma	243.58	15.92	60	9274	2597	64486801
Intraocular pressure increased	203.85	15.92	67	9267	8235	64481163
Choroidal detachment	203.31	15.92	39	9295	503	64488895
Choroidal effusion	168.46	15.92	34	9300	578	64488820
Metabolic acidosis	142.90	15.92	102	9232	70856	64418542
Hair follicle tumour benign	130.71	15.92	26	9308	409	64488989
Idiopathic intracranial hypertension	128.74	15.92	36	9298	2557	64486841
Off label use	88.96	15.92	245	9089	632561	63856837
Papilloedema	87.03	15.92	32	9302	5473	64483925
Intracranial pressure increased	83.08	15.92	33	9301	6956	64482442
Ocular surface disease	62.55	15.92	11	9323	84	64489314
Hypercapnia	60.24	15.92	27	9307	7667	64481731
Corneal oedema	57.85	15.92	19	9315	2324	64487074
Glaucoma	53.76	15.92	32	9302	16316	64473082
Complications of bone marrow transplant	51.48	15.92	13	9321	622	64488776
Toxic epidermal necrolysis	49.77	15.92	42	9292	37124	64452274
Transmission of an infectious agent via product	49.10	15.92	10	9324	178	64489220
Hepatosplenic T-cell lymphoma	48.15	15.92	13	9321	809	64488589
Product contamination microbial	47.23	15.92	13	9321	870	64488528
Hyphaema	46.19	15.92	12	9322	643	64488755
Photophobia	44.59	15.92	29	9305	17264	64472134
Macular detachment	43.06	15.92	9	9325	183	64489215
Visual impairment	42.52	15.92	53	9281	74024	64415374
Drug ineffective	41.46	15.92	234	9100	840013	63649385
Retinal detachment	41.10	15.92	21	9313	7955	64481443
Visual acuity reduced	39.10	15.92	32	9302	27109	64462289
Flat anterior chamber of eye	38.84	15.92	8	9326	151	64489247
Vision blurred	37.20	15.92	55	9279	90261	64399137
Ophthalmic vein thrombosis	36.51	15.92	8	9326	205	64489193
Myopia	34.51	15.92	12	9322	1746	64487652
Endophthalmitis	33.20	15.92	16	9318	5349	64484049
Acidosis hyperchloraemic	31.59	15.92	9	9325	683	64488715
Hypotony of eye	30.36	15.92	7	9327	227	64489171
Cerebral venous sinus thrombosis	30.12	15.92	11	9323	1844	64487554
Acidosis	29.96	15.92	23	9311	17772	64471626
Visual field defect	29.56	15.92	17	9317	8129	64481269
Corneal opacity	29.21	15.92	9	9325	896	64488502
Acute generalised exanthematous pustulosis	27.76	15.92	20	9314	14038	64475360
Trabeculectomy	27.32	15.92	5	9329	49	64489349
Photocoagulation	26.36	15.92	4	9330	10	64489388
Iridocyclitis	24.84	15.92	11	9323	3034	64486364
Retinal vascular occlusion	24.75	15.92	7	9327	517	64488881
Vitreous disorder	24.70	15.92	6	9328	244	64489154
Intellectual disability	24.17	15.92	8	9326	1002	64488396
Retroperitoneal oedema	24.04	15.92	4	9330	21	64489377
Dysphoria	23.91	15.92	12	9322	4376	64485022
Diplopia	23.67	15.92	24	9310	26741	64462657
Lens dislocation	22.75	15.92	5	9329	130	64489268
Appetite disorder	22.16	15.92	13	9321	6448	64482950
Multiple-drug resistance	22.08	15.92	13	9321	6489	64482909
Blindness	21.80	15.92	21	9313	21998	64467400
Somnolence	20.99	15.92	71	9263	203574	64285824
Meningitis aseptic	20.90	15.92	12	9322	5718	64483680
Psychiatric decompensation	20.42	15.92	9	9325	2454	64486944
CSF pressure increased	20.25	15.92	5	9329	218	64489180
Retinopathy haemorrhagic	20.22	15.92	4	9330	61	64489337
Drug resistance	19.94	15.92	25	9309	35077	64454321
Burkholderia test positive	19.71	15.92	6	9328	573	64488825
Myasthenic syndrome	19.08	15.92	6	9328	639	64488759
Sickle cell anaemia with crisis	19.01	15.92	11	9323	5321	64484077
Aggression	18.80	15.92	28	9306	46204	64443194
Optic disc haemorrhage	18.79	15.92	4	9330	89	64489309
Eye pain	18.73	15.92	23	9311	31602	64457796
Intraventricular haemorrhage	18.72	15.92	10	9324	4143	64485255
Persecutory delusion	18.71	15.92	10	9324	4148	64485250
Prostaglandin analogue periorbitopathy	18.70	15.92	3	9331	12	64489386
Haemorrhagic diathesis	18.66	15.92	11	9323	5503	64483895
Arthritis infective	18.64	15.92	12	9322	7018	64482380
Acute respiratory failure	18.55	15.92	29	9305	49905	64439493
Visual acuity tests abnormal	17.71	15.92	4	9330	118	64489280
Product use in unapproved indication	17.69	15.92	61	9273	176557	64312841
Brain stem haematoma	17.68	15.92	4	9330	119	64489279
Crystalluria	17.53	15.92	6	9328	832	64488566
Punctate keratitis	17.35	15.92	6	9328	859	64488539
Dysmetria	17.14	15.92	6	9328	890	64488508
Drug reaction with eosinophilia and systemic symptoms	16.78	15.92	29	9305	54188	64435210
Respiratory alkalosis	16.50	15.92	9	9325	3888	64485510
Conjunctival hyperaemia	16.49	15.92	9	9325	3890	64485508
Hyperventilation	16.48	15.92	11	9323	6829	64482569
Pupillary block	16.43	15.92	3	9331	29	64489369

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	S01EC01	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Carbonic anhydrase inhibitors
FDA CS	M0020790	Sulfonamides
FDA MoA	N0000000235	Carbonic Anhydrase Inhibitors
FDA EPC	N0000175517	Carbonic Anhydrase Inhibitor
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002257	Carbonic Anhydrase Inhibitors
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004232	Diuretics
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D045283	Natriuretic Agents
CHEBI has role	CHEBI:23018	EC 4.2.1.1 inhibitor
CHEBI has role	CHEBI:35498	diuretics
CHEBI has role	CHEBI:35623	anticonvulsants

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Malignant glaucoma	indication	10100008
Anoxia due to high altitude	indication	42883007
Absence seizure	indication	79631006
Open-angle glaucoma	indication	84494001	DOID:1067
Secondary glaucoma	indication	95717004
Edema	indication	267038008
Peripheral edema	indication	271809000
Angle-closure glaucoma	indication	392291006	DOID:13550
Peripheral Edema due to Chronic Heart Failure	indication
Metabolic alkalosis	off-label use	1388004
Myoclonic seizure	off-label use	37356005
Idiopathic intracranial hypertension	off-label use	68267002	DOID:11459
Benign intracranial hypertension	off-label use	68267002	DOID:11459
Familial hypokalemic periodic paralysis	off-label use	82732003	DOID:14452
Epilepsy	off-label use	84757009	DOID:1826
Obstructive hydrocephalus	off-label use	230746009	DOID:14159
Familial periodic paralysis	off-label use	267607008	DOID:1029
Tonic-clonic epilepsy	off-label use	352818000	DOID:7725
Simple partial seizure	off-label use	117891000119100
Urine Alkalinization	off-label use
Hydrocephalus due to Intraventricular Hemorrhage	off-label use
Mixed Epilepsy	off-label use
Renal tubular acidosis	contraindication	1776003	DOID:14219
Respiratory acidosis	contraindication	12326000
Hyperkalemia	contraindication	14140009
Metabolic acidosis, normal anion gap, acidifying salts	contraindication	18104000
Diabetes mellitus type 2	contraindication	44054006	DOID:9352
Diabetes mellitus type 1	contraindication	46635009	DOID:9744
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Decreased respiratory function	contraindication	80954004
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Disease of blood AND/OR blood-forming organ	contraindication	191124002	DOID:74
Disease of liver	contraindication	235856003	DOID:409
Disorder of electrolytes	contraindication	237840007
Primary adrenocortical insufficiency	contraindication	373662000
Recurrent Calcium Renal Calculi	contraindication

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Mild congestive heart failure	Indication
Dogs	Rapid reduction of intraocular pressure	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Vetamox Soluble Powder	Zoetis Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.04	acidic
pKa2	9.21	acidic
pKa3	1.84	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN	INHIBITOR	Ki	8.60	CHEMBL	CHEMBL
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN	INHIBITOR	Ki	7.92	CHEMBL	CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN	INHIBITOR	Ki	7.96	CHEMBL	CHEMBL
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN	INHIBITOR	Ki	8.48	CHEMBL	CHEMBL
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	7.22	CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	7.27	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	8.60	CHEMBL
Carbonic anhydrase 3	Enzyme	P07451	CAH3_HUMAN		Ki	8.51	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	7.96	CHEMBL
Carbonic anhydrase 14	Enzyme	Q9ULX7	CAH14_HUMAN		Ki	7.39	CHEMBL
Carbonic anhydrase 13	Enzyme	Q8N1Q1	CAH13_HUMAN		Ki	8.24	CHEMBL
Carbonic anhydrase	Enzyme	O43570 P00915 P00918 P07451 P22748 P23280 P35218 P43166 Q16790 Q8N1Q1 Q9ULX7 Q9Y2D0	CAH12_HUMAN CAH1_HUMAN CAH2_HUMAN CAH3_HUMAN CAH4_HUMAN CAH6_HUMAN CAH5A_HUMAN CAH7_HUMAN CAH9_HUMAN CAH13_HUMAN CAH14_HUMAN CAH5B_HUMAN		Ki	9.10	CHEMBL
Carbonic anhydrase V	Enzyme	P35218 Q9Y2D0	CAH5A_HUMAN CAH5B_HUMAN		Ki	8.74	CHEMBL
Carbonic anhydrase-related protein 11	Enzyme	O75493	CAH11_HUMAN		Ki	8.24	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	8.05	CHEMBL
Aquaporin-1	Transporter	P29972	AQP1_HUMAN				WOMBAT-PK
Carbonic anhydrase	Enzyme		CYNT_HELPY		Ki	7.70	CHEMBL
Carbonic anhydrase 13	Enzyme		CAH13_MOUSE		Ki	7.77	CHEMBL
Carbonic anhydrase 4	Enzyme		CAH4_BOVIN		Ki	7.15	CHEMBL
Carbonic anhydrase 7	Enzyme		CAH7_MOUSE		Ki	7.80	CHEMBL
Carbonic anhydrase	Enzyme		CAH_METTE		Ki	7.22	CHEMBL
Carbonic anhydrase	Enzyme		Q50565_METTH		Ki	4.92	CHEMBL
Carbonic anhydrase 15	Enzyme		CAH15_MOUSE		Ki	7.14	CHEMBL
Carbonic anhydrase	Enzyme		CAN_YEAST		Ki	7.09	CHEMBL
Carbonic anhydrase	Enzyme		CAN_CANAL		Ki	7.40	CHEMBL
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase	Enzyme		P96878_MYCTU		Ki	7.92	CHEMBL
Carbonic anhydrase	Enzyme		Q6FTL6_CANGA		Ki	7.96	CHEMBL
Alpha carbonic anhydrase	Enzyme		B5SU02_9CNID		Ki	7.80	CHEMBL
Endochitinase	Enzyme		CHIT_YEAST		Ki	4.68	CHEMBL
Carbonic anhydrase	Enzyme		C0IX24_9CNID		Ki	7.13	CHEMBL
Carbonic anhydrase 2	Enzyme		Q3I4V7_CRYNV		Ki	8	CHEMBL
Carbonic anhydrase	Enzyme		Q2PCB5_DICLA		Ki	5.24	CHEMBL
Astrosclerin-3	Enzyme		A6YCJ1_9METZ		Ki	7.29	CHEMBL
Beta-carbonic anhydrase 1	Enzyme		MTCA1_MYCTU		Ki	6.60	CHEMBL
Delta carbonic anhydrase	Unclassified		Q5U9J1_THAWE		Ki	7.08	CHEMBL
Carbonic anhydrase 2	Enzyme		MTCA2_MYCTU		Ki	8.05	CHEMBL
Carbonic anhydrase 2	Enzyme		CAH2_BOVIN		IC50	6.02	CHEMBL
Carbonic anhydrase	Enzyme		CAH2_BOVIN CAH6_BOVIN CAH3_BOVIN CAH4_BOVIN		IC50	7.80	CHEMBL
Carbonic anhydrase	Enzyme		CAHX_FLABI		Ki	7.57	CHEMBL
Carbonic anhydrase 3	Enzyme		CAH3_BOVIN		Ki	4.08	CHEMBL
Carbonic anhydrase	Enzyme		Q5TU56_ANOGA		Ki	7.56	CHEMBL
Carbonic anhydrase	Enzyme		Q9HVB9_PSEAE		Ki	7.12	CHEMBL
Carbonic anhydrase, alpha family	Unclassified		Q31FD6_HYDCU		Ki	8.37	CHEMBL
Carbonate dehydratase	Enzyme		B2V8E3_SULSY		Ki	8.35	CHEMBL
Carbonic anhydrase 2, isoform A; LD26647p	Enzyme		Q9VTU8_DROME		Ki	7.11	CHEMBL
Carbonic anhydrase 1; GH09688p	Enzyme		Q9V396_DROME		Ki	6.97	CHEMBL

External reference:

ID	Source
4017898	VUID
N0000146250	NUI
D00218	KEGG_DRUG
1424-27-7	SECONDARY_CAS_RN
167	RXNORM
C0000981	UMLSCUI
CHEBI:27690	CHEBI
AZM	PDB_CHEM_ID
CHEMBL20	ChEMBL_ID
DB00819	DRUGBANK_ID
CHEMBL1200814	ChEMBL_ID
D000086	MESH_DESCRIPTOR_UI
1986	PUBCHEM_CID
481	INN_ID
6792	IUPHAR_LIGAND_ID
O3FX965V0I	UNII
2596	MMSL
4121	MMSL
814	MMSL
d00161	MMSL
002286	NDDF
002287	NDDF
4017898	VANDF
4017899	VANDF
33664007	SNOMEDCT_US
372709008	SNOMEDCT_US
72469007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9006	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	20 sections
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9503	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	20 sections
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9503	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	20 sections
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1050	TABLET	250 mg	ORAL	ANDA	19 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6663	TABLET	250 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6663	TABLET	250 mg	ORAL	ANDA	18 sections
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-567	TABLET	250 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	16729-331	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	21 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-120	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	11 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-287	TABLET	125 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-287	TABLET	125 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-288	TABLET	250 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-288	TABLET	250 mg	ORAL	ANDA	18 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-313	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	16 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-787	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	12 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	29033-030	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	22 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	39822-0190	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	13 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	42291-089	TABLET	125 mg	ORAL	ANDA	18 sections
acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	42291-090	TABLET	250 mg	ORAL	ANDA	18 sections
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42291-103	TABLET	250 mg	ORAL	ANDA	19 sections
ACETAZOLAMIDE EXTENDED-RELEASE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-243	CAPSULE	500 mg	ORAL	ANDA	21 sections
ACETAZOLAMIDE EXTENDED-RELEASE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-243	CAPSULE	500 mg	ORAL	ANDA	21 sections
Acetazolamide	Human Prescription Drug Label	1	46708-349	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	21 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0577	TABLET	125 mg	ORAL	ANDA	19 sections
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3003	TABLET	250 mg	ORAL	ANDA	19 sections
AcetaZOLAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3003	TABLET	250 mg	ORAL	ANDA	19 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3132	CAPSULE, EXTENDED RELEASE	500 mg	ORAL	ANDA	11 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4511	TABLET	125 mg	ORAL	ANDA	18 sections
Acetazolamide	Human Prescription Drug Label	1	50090-5217	TABLET	125 mg	ORAL	ANDA	18 sections
Acetazolamide	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5593	TABLET	250 mg	ORAL	ANDA	17 sections